IONS
Price:
$46.89
Market Cap:
$6.86B
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with ...[Read more]
Industry
Biotechnology
IPO Date
1991-05-17
Stock Exchange
NASDAQ
Ticker
IONS
According to Ionis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -115.80%. This represents a change of 278.59% compared to the average of -30.59% of the last 4 quarters.
The mean historical ROE of Ionis Pharmaceuticals, Inc. over the last ten years is -30.51%. The current -115.80% ROE has changed 279.57% with respect to the historical average. Over the past ten years (40 quarters), IONS's ROE was at its highest in in the December 2018 quarter at 30.54%. The ROE was at its lowest in in the June 2016 quarter at -51.12%.
Average
-30.51%
Median
-29.54%
Minimum
-94.72%
Maximum
26.12%
Discovering the peaks and valleys of Ionis Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.15%
Maximum Annual ROE = 26.12%
Minimum Annual Increase = -1547.54%
Minimum Annual ROE = -94.72%
Year | ROE | Change |
---|---|---|
2023 | -94.72% | 101.03% |
2022 | -47.12% | 1.15% |
2021 | -3.76% | -93.50% |
2020 | -57.77% | -389.05% |
2019 | 19.99% | -23.48% |
2018 | 26.12% | -1547.54% |
2017 | -1.80% | -97.92% |
2016 | -86.93% | 97.73% |
2015 | -43.97% | 190.72% |
2014 | -15.12% | -5.64% |
The current ROE of Ionis Pharmaceuticals, Inc. (IONS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-48.53%
5-year avg
-36.68%
10-year avg
-30.51%
Ionis Pharmaceuticals, Inc.’s ROE is less than Arrowhead Pharmaceuticals, Inc. (0%), greater than BioMarin Pharmaceutical Inc. (-172.90%), less than Incyte Corporation (5.08%), less than Apellis Pharmaceuticals, Inc. (2.10%), greater than Viking Therapeutics, Inc. (-139.02%), greater than Intercept Pharmaceuticals, Inc. (-15.05%), greater than Terns Pharmaceuticals, Inc. (-78.24%), greater than Akero Therapeutics, Inc. (-39.58%), greater than Reata Pharmaceuticals, Inc. (-29.56%), less than Seagen Inc. (19.32%), greater than Alnylam Pharmaceuticals, Inc. (-28.06%), less than Exelixis, Inc. (47.92%), less than Halozyme Therapeutics, Inc. (15.80%), less than PTC Therapeutics, Inc. (168.60%), less than Krystal Biotech, Inc. (57.03%), less than Sarepta Therapeutics, Inc. (13.36%), less than Iovance Biotherapeutics, Inc. (5.17%), greater than Madrigal Pharmaceuticals, Inc. (-65.04%), greater than null (-95.61%),
Company | ROE | Market cap |
---|---|---|
0% | $2.76B | |
-172.90% | $16.01B | |
5.08% | $11.80B | |
2.10% | $5.00B | |
-139.02% | $6.00B | |
-15.05% | $794.69M | |
-78.24% | $549.60M | |
-39.58% | $1.83B | |
-29.56% | $6.57B | |
19.32% | $43.15B | |
-28.06% | $31.68B | |
47.92% | $7.17B | |
15.80% | $7.50B | |
168.60% | $2.43B | |
57.03% | $5.29B | |
13.36% | $12.29B | |
5.17% | $3.04B | |
-65.04% | $5.30B | |
-95.61% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ionis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Ionis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Ionis Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Ionis Pharmaceuticals, Inc. (IONS)?
What is the highest ROE for Ionis Pharmaceuticals, Inc. (IONS)?
What is the 3-year average ROE for Ionis Pharmaceuticals, Inc. (IONS)?
What is the 5-year average ROE for Ionis Pharmaceuticals, Inc. (IONS)?
How does the current ROE for Ionis Pharmaceuticals, Inc. (IONS) compare to its historical average?